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Heat shock protein family B (small) member 7 
(HSPB7) is a unique, relatively unexplored member 
within the family of human small heat shock proteins 
(HSPBs). Unlike most HSPB family members, HSPB7 
does not oligomerize and so far has not been shown to 
associate with any other member of the HSPB family. 
Intriguingly, it was found to be the most potent 
member within the HSPB family to prevent 
aggregation of proteins with expanded polyglutamine 
(polyQ) stretches. How HSPB7 suppresses polyQ 
aggregation has remained elusive so far. Here, using 
several experimental strategies, including in vitro 
aggregation assays and immunoblotting and –
fluorescence approaches, we show that the polyQ 
aggregation–inhibiting activity of HSPB7 is fully 
dependent on its flexible N-terminal domain (NTD). 
We observed that the NTD of HSPB7 is both required 
for association with and inhibition of polyQ 
aggregation. Remarkably, replacing the NTD of 
HSPB1, which itself cannot suppress polyQ 
aggregation, with the NTD of HSPB7 resulted in a 
hybrid protein that gained anti-polyQ aggregation 
activity. The hybrid NTDHSPB7-HSPB1 protein 
displayed a reduction in oligomer size and, unlike 
wildtype HSPB1, associated with polyQ. However, 
experiments with phospho-mimicking HSPB1 mutants 
revealed that de-oligomerization of HSPB1 alone does 
not suffice to gain polyQ aggregation–inhibiting 
activity. Together, our results reveal that the NTD of 
HSPB7 is both necessary and sufficient to bind to and 
suppress the aggregation of polyQ-containing 
proteins.  
 
Small heat shock proteins (HSPBs) are described 
as a series of small molecular size chaperones 
composed of a flexible N-terminal domain (NTD) and 
a flexible C-terminal domain (CTD) flanking a 
conserved α-crystallin domain (ACD) (1-3). The 
human family of HSPBs is comprised of 10 members 
(1). Most of these form highly dynamic oligomeric 
complexes (3,4). Besides forming homo-oligomeric 
complexes, some HSPBs can also form hetero-
oligomers with specific other HSPBs (4,5). Exceptions 
to this paradigm are HSPB8, which forms a chaperone 
complex with BAG3 and Hsp70 (6,7), and HSPB7 
which has no known other chaperone partners and does 
not form large oligomers (7,8).  
Unlike the human oligomeric HSPB family 
members, HSPB7 overexpression does not enhance 
the cellular capacity to refold heat-unfolded luciferase 
(8) nor leads to suppression of the heat-inducd 
aggregation of cytosolic proteins (9). Instead, within 
the human HSPB family, HSPB7 is the strongest 
suppressor of aggregation of polyglutamine containing 
proteins (8) that cause diseases like Spinocerebellar 
Ataxia’s, Kennedy’s disease, and Huntington’s disease 
(HD) (10,11). These diseases are caused by expansions 
of CAG triplet repeats coding for abnormally long 
polyglutamine (polyQ) stretches (11). The size of these 
expansions are inversely correlated with the onset age 
of these diseases and to the aggregation propensity of 
the respective proteins (10). Unlike heat-induced 
aggregates that are generally driven by hydrophobic 
interactions (12), polyQ aggregation is suggested to be 
driven by hydrogen bonding and beta-hairpin 
structures (13,14) potentially explaining the different 
dependence on chaperone activity for suppression of 
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polyQ aggregation. However, why HSPB7 stands out 
as most potent suppressor of polyQ aggregation within 
the HSPB family, has remained an enigma. Previously, 
we showed that HSPB7 requires (macro) autophagy 
for its suppressive action on polyQ aggregation (8). 
However, HSPB7 differs from other autophagy related 
suppressors like Alfy, as it cannot act on preformed 
aggregates to fullfill its function (15). One model that 
explains this finding predicts that HSPB7 is present 
during aggregate formation and binds these 
protofibrils to maintain early aggregates in a state 
competent for processing by the autophagic machinery 
(16).  
In this manuscript, we investigated which 
characteristics of HSPB7 are required to chaperone 
polyQ proteins and prevent their aggregation. HSPB7 
acts directly on the aggregation process as 
recombinant HSPB7 can delay in vitro polyQ 
aggregation, whereas HSPB1 cannot. HSPB7 acts 
mainly on regions flanking the polyQ and not on the 
amyloid core itself. In cells, this remarkable 
suppression depends on the N-terminus of HSPB7 that 
is predicted as an intrinsically disordered region. 
While the N-terminus by itself is not capable of 
supressing aggregation, fusion to the alpha crystallin 
domain of HSPB1 results in a hybrid protein with 
polyQ anti aggregation properties. In summary, the full 
and unique N-terminal domain is key to the specific 




The full NTD is required for HSPB7 to prevent polyQ 
aggregation 
Within the HSPB family, cell-based analyses had 
revealed that HSPB7 stands out as a chaperone that is 
the most capable to prevent aggregate formation by 
amyloidogenic polypeptides including polyglutamine 
(polyQ) containing proteins (8). First, we asked 
whether this protective function of HSPB7 against 
polyQ aggregation seen in cells is related to a direct 
action of the chaperone on the substrate. Hereto, we 
incubated a purified exon-1 fragment of mutant 
Huntingtin with 48 glutamines (mHttQ48) with either 
purified HSPB7 or HSPB1 (with HSPB1 acting as 
control as it is unable unable to protect against polyQ 
aggregation in cells (8)). Analysing the ratio of 
soluble:insoluble mHttQ48 by gel-electrophoresis (9), 
we found that with time, the amount of soluble 
mHttQ48 declined and appeared as aggregated 
material in the stacking gel (Figure 1, A, B). The rate 
of decline in the soluble:insoluble ratio of mHttQ48 
was unaffected by co-incubation with HSPB1 but 
clearly slowed down by the presence of HSPB7 
(Figure 1, A, B) meaning that HSPB7 acts directly on 
the aggregation process.  
Next, we asked what structural characteristics in 
HSPB7 specifies this activity towards suppressing 
aggregation of polyQ proteins. The NTDs and CTDs 
of HSPBs display the highest level of variability and 
have been suggested to be crucial for their differential 
function (17,18). Our earlier data had revealed that the 
CTD of HSPB7 is not required for its activity to 
prevent polyQ aggregation (8). So, we focused our 
attention on the NTD of HSPB7 and noted a serine-
rich stretch (SRS) (Figure 1, C and Supporting 
Information 1, A) that is not found in other HSPB 
members. Interestingly, a serine-rich stretch has been 
identified as a crucial segment in the ability of 
DNAJB6, a Hsp70 co-chaperone, to suppress polyQ 
aggregation (19,20). Although structurally distinct 
(Supporting Information 1, A ) we first set out to test 
the importance of the NTD in HSPB7, and in particular 
its SRS, in its action to supress polyQ aggregation by 
generating a series of NTD truncations of HSPB7 
mutants (Figure 1, C) that we co-expressed in cells 
together with a exon-1 fragment of Huntingtin with 74 
glutamines tagged to GFP (mHttQ74-GFP). In contrast 
to our speculations, deleting the SRS from HSPB7 (v5-
HSPB7△S17-29) did not result in a loss of its anti-
aggregation activity (Figure 1, D-F), despite its 
relatively lower expression as compared to that of 
wildtype HSPB7 (Supporting Information 1, B). 
However, a gradual decline in anti-aggregation activity 
was found upon progressive NTD deletion with the 
complete deletion of the NTD (v5-HSPB7△73), being 
inactive (Figure 1, D-F, Supporting Information 1, B). 
None of the HSPB7 variants caused an induction of the 
heat shock response, evidenced by the absence of 
induced expression of HSPA6, an exclusive HSF-1 
regulated chaperone (21,22) (Supporting Information 
1, C). Also the HSF-1 regulated chaperone DNAJB1, 
that -when overexpressed alone- can also lead to 
suppression of polyQ aggregation in these cells (23,24) 
was not elevated by the expression of any of the 
HSPB7 variants (Supporting Information 1, C), 
implying that it is unlikely that their (remaining) 
protective effects are due to upregulation of 
endogeneous stress responses. Finally, endogenous 
expression of HSPB7 is undetetcable in these cells 
irrespective of expression of the HSPB7 variants (not 
shown) implying that protective effects of the mutants 
cannot be attributed to formation of complexes 
between full length endogenous and the ectopically 
expressed HSPB7 variants. 
 
Fusing the NTD of HSPB7 to polyQ does not prevent 
polyQ aggrgation 
Three algorithms designed to predict  
intrinsically disordered regions (25,26) suggest that 
the NTD of HSB7 is highly disordered (Supporting 
Information 1, D) and reminiscent of proteins involved 
in phase separation (27-29) In fact, HSPB7 has been 
shown to be associated with intranuclear RNA 
speckles (SC35 speckles) and the fusion of its NTD to 
other small HSPBs like HSPB1 (of which the NTD is 
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less disordered: Supporting Information 1, D and E) 
suffices to drive their association with these SC35 
speckles, suggesting it might induce phase separation 
of the proteins it interacts with to prevent 
amyloidogenesis (30). Whereas for polyQ proteins, a 
protective role for chaperone-mediated phase 
separation has not been established, it has been 
speculated that in yeast compartmentalization of 
polyQ proteins into so-called insoluble protein deposit 
(iPODs) may have physiological, cell protective 
relevance (31,32). In HEK293 cells, wild type HSPB7 
(v5-HSPB7WT) indeed colocalizes with mHttQ74-GFP 
inclusions and this co-localization is much reduced for 
the NTD deletion mutant (v5-HSPB7△73) (Figure 1, G). 
Moreover, whereas full length HSPB7 was bound to 
mHttQ74-GFP in co-immunoprecipitation 
experiments the NTD deletion mutant (v5-HSPB7△73) 
was not (Figure 1, H). This could suggest that binding 
of HSPB7 to polyQ proteins drives its phase separation 
and hence prevents its aggregation into SDS-insoluble 
amyloids. Our initial attempts to co-express mHttQ74-
GFP with only the NTD of HSPB7 (NTDHSPB7) failed 
as the NTD alone is not stable when expressed in cells 
(Supporting Information 2, A). To test whether the 
predicted major IDR fragment of HSPB7 suffices to 
prevent polyQ aggregation, we therefore tagged the 
polyQ fragment directly with the NTD of HSPB7 
(Figure 2, A-D, Supporting Information 2, B). 
However, for both fragments with either 43 or 74 CAG 
repeats, tagging with the NTDHSPB7 did not prevent 
polyQ aggregation, but rather enhanced it. (Figure 2, 
A-D). These data imply binding of HSPB7 to polyQ 
proteins and a putative subsequent phase separation 
driven by its NTD as such is insufficient to prevent 
polyQ aggregation. Direct fusion of the full length 
HSPB7 to polyQ74 did prevent aggregation indicating 
that the NTD in these hybrid fusion proteins is 
functional (Figure 2, E and F, Supporting Information 
2, C). Since we previously showed that the CTD of 
HSPB7 is dispensable for its action on polyQ (8), the 
combined data suggest that interaction of a 
(monomeric) HSPB7 via its NTD to polyQ proteins 
and the presence of the ACD of HSPB7 suffice to 
prevent mHtt aggregation. 
 
Fusion of the NTD of HSPB7 to HSPB1 is sufficient 
to convey HSPB1 with anti-polyQ aggregation 
activity 
We next hypothesized that fusing the NTD of 
HSPB7 to the ACD of other HSPBs may turn these 
into polyQ aggregation preventive chaperones. As 
mentioned above, HSPB7 does not form homo- nor 
hetero-oligomers with any of the HSPBs, so targeting 
the other HSPBs to polyQ aggregates via hetero-
oligomerisation is unlikely to occur. To test whether 
the NTD of HSPB7 could turn another HSPB protein 
into an effective inhibitor of polyQ aggregation we 
choose HSPB1, as neither its presence in vitro  
(Figure 1, A-B) nor its overexpression in cells (Figure 
3, B-D, Supporting Information 3, A) could inhibit 
polyQ aggregation. Strikingly, expression of a fusion 
of the NTD of HSPB7 with the ACD and C-terminal 
domain of HSPB1 (NTDHSPB7-HSPB1) lead to reduced 
mHttQ74-GFP aggregation comparable to the effect of 
HSPB7WT expression (Figure 3, A-D). This result 
indicated that the conserved ACD is a necessary 
structural requirement for HSPB7 to prevent polyQ 
aggregation. Strikingly, this requirement is not 
restricted to the ACD of HSPB7 as also the ACD of 
HSPB1 can exert this function. Indeed, a fusion of the 
NTDHSPB7 to mRFP (as a control) did not generate a 
hybrid protein that could prevent mHttQ74 
aggregation (Supporting Information 3, B and C). 
In line with the biochemical data, we found that 
whereas wild type HSPB1 did not co-localize with 
mHttQ74-GFP, the NTDHSPB7-HSPB1 hybrid did 
(Figure 3, E). Inversely, replacing the NTD of HSPB7 
with the NTD of HSPB1 resulted in a hybrid protein 
(NTDHSPB1-HSPB7) that had lost its anti-polyQ-
aggregation activity (Figure 3, F and G, Supporting 
Information 3, D) and no longer co-localized with the 
polyQ aggregates (Figure 3, H).  
The co-localization of polyQ with HSPB7 and 
NTDHSPB7-HSPB1 suggested that the NTD of HSPB7 
is both required and sufficient for association of small 
HSPB proteins with polyQ proteins. This was 
confirmed by GFP pull-down experiments with 
mHttQ74-GFP. Whereas HSPB7WT was clearly co-
precipitating with mHttQ74-GFP, HSPB7△73 did not 
(Figure 1, H). Inversely, whereas HSPB1WT did not co-
IP with mHttQ74-GFP, NTDHSPB7-HSPB1 did (Figure 
3, I). These data confirm that the NTD of HSPB7 
drives the interaction between HSPB7 and polyQ 
proteins. Since the interaction in our co-IP experiments 
is performed on soluble material, these data further 
suggest that the N-terminus of HSPB7 can already 
bind to polyQ prior to its insolubilization into high 
molecular weight aggregates. This mode of action is 
analogous to those of other small HSPs that need to be 
present prior to aggregation to be most active as well 
(7,33). Our data suggest that the flanking regions, here 
the NTD, are required and sufficient for targeting small 
HSPs to their substrates and that the ACD enables the 
suppression of aggregation.  
 
Shifting the HSPB oligomeric status is not 
sufficient for polyQ aggregation prevention 
How can the NTD of HSPB7 turn HSPB1 into a 
protein that now can bind to polyQ proteins and 
suppress their aggregation? Since, HSPB7 does not 
form oligomers like the canonical small HSPs 
including HSPB1 (8), we determined the role of the 
HSPB7-NTD in the oligomerization process. Sucrose 
gradient centrifugation of whole cell extracts 
confirmed that wild type HSPB1 is polydispersed 
(Figure 4, A), reminiscent of being present as dynamic 
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oligomers in cells. In contrast, wild type HSPB7 
predominantly runs in a monodispersed peak, likely 
representing dimers. (Figure 4, A). Deletion of the 
NTD from HSPB7 (HSPB7△73 ) does not change this 
behavior (Figure 4, A) , implying that loss of its anti-
aggregation activity is not related to a change into a 
more polydispersed form. Importantly, fusion of the 
HSPB7-NTD to HSPB1 (NTDHSPB7-HSPB1 ) has a 
strong impact on the oligomeric properties of HSPB1. 
The NTDHSPB7-HSPB1 chimera was found to sediment 
in the same fractions as HSPB7, representing smaller 
oligomeric species such as dimers (Figure 4, A). These 
data indicate that the presence of the HSPB7-NTD 
inhibits the association of the HSPB to higher 
oligomeric asslemblies and might point to an 
association between the oligomeric status of HSPBs 
and their ability to prevent polyQ aggregation. 
To test whether the shift in oligomerization 
behavior suffices to turn HSPB1 into a polyQ 
aggregation preventing chaperone, we used HSPB1-
phosphorylation mutants that also impede the 
oligomeric status. HSPB1 can be phosphorylated at 
three serines which drives its de-oligomerization 
(34,35). Mutation of these three serines (S) into 
aspartic acid (D) (HSPB1DDD) simulates the 
oligomeric behavior of this phosphorylated form of 
HSPB1 (34) (Figure 4, B; Supporting Information 3, 
E), whilst mutating these serines into alanines 
(HSPB1AAA) simulate the un-phosphorylated form of 
HSPB1 forming, on average, larger oligomeric 
complexes (34) (Figure 4, B; Supporting Information 
3, F). However, expression of neither HSPB1DDD nor 
HSPB1AAA was found to reduce mHttQ74-GFP 
aggregation (Figure 4, C, Supporting Information 3, F). 
These results suggest that de-oligomerization alone is 
not sufficient for HSPB1 to prevent polyQ aggregation 
and pinpoints the need for the presence of the HspB7-
NTD for polyQ protein recognition. 
 
The ability of HSPB7 to prevent polyQ aggregation 
depends on the regions flanking the polyQ stretch. 
The polyQ stretch in (mutant) huntingtin is 
flanked by a 17 amino acid long N-terminal (N17) 
domain (36) and a proline-rich region (PRR) C-
terminal (37) of the poly-Q stretch. These flanking 
regions not only affect the propensity of aggregation 
of the polyQ protein, but also affect how chaperones 
may or may not be able to delay the onset of 
aggregation (10,36,37). Whereas some chaperones 
like DNAJB6 can prevent initiation of aggregation 
independently of such flanking regions by directly 
interacting with the amyloidogenic polyQ region (10), 
other chaperones like TRiC mediate their anti-
aggregation effects via binding to the N17 domain of 
Huntingtin (10,38). To test how HSPB7 acts, we co-
expressed it with 4 different mHtt constructs (Figure 5, 
A-D) one containing both the intact N17 domain and 
PRR, one with a truncated N17, one with a truncated 
PRR, or one in which both the N17 and PPR are 
truncated. HSPB7 could suppress the aggregation of 
all these variants, except the one with a truncation of 
both the N17 domain and the PPR constructs (Figure 
5, A-D). This implies that HSPB7 does not directly act 
on the amyloidogenic polyQ region but requires either 
the N17 domain and/or the PPR to mediate its anti-




Here we show that HSPB7, a non-canonical 
member of the human HSPB family of small heat 
shock proteins, prevents aggregate formation by 
directly acting on polyglutamine (polyQ) containing 
proteins via its unique N-terminal domain. This NTD 
facilitates binding of HSPB7 to polyQ proteins. 
Intriguingly, the NTD is sufficient to provide another 
member of the HSPB family, HSPB1, with the 
capacity to bind to and suppress aggregation of polyQ 
proteins.  
HSPB7, unlike canonical HSPBs, is not forming 
large oligomeric species (8). Although replacing the 
NTD of HSPB1 by the NTD of HSPB7 leads to a 
reduction in the average oligomeric size of the hybrid 
protein, de-oligomerization alone was found 
insufficient to confer anti-polyQ aggregation activity 
to HSPB1. Rather, the NTD of HSPB7 seems to confer 
substrate binding capacity to HSPBs as its deletion 
from HSPB7 (HSPB7△73) lead to a loss of binding and 
suppression capacity. Currently it is unclear to which 
polyQ species HSPB7 is binding. Our co-IP 
experiments, perfomed using soluble material, suggest 
that HSPB7 binds to early profibrillar species. The fact 
that HSPB7 is associated with the (later) polyQ 
inclusions (IF) confirms its capacity to bind to polyQ 
species, but may also reflect a failed function. 
Interestingly, the NTD of HSPB7 is intrinsically 
disordered (27), characteristic of proteins involved in 
phase separation (39,40). Although we did not observe 
any HSPB7-mediated demixing, our results do not rule 
out a role of the NTD in phase separation. The unique 
properties of the NTD of HSPB7 in the context of an 
ACD are clearly sufficient to drive inhibition of polyQ 
aggregation. The notion that this suppressive nature 
gradually declines with the progressive shortening of 
the NTD (Figure 1) is arguing against the presence of 
specific structural motifs within the NTD. Indeed for 
other intrinsically disordered regions, it has been 
shown that rather than amino acid order and chemical 
composition, function is determined by the length of 
the IDR (40). These results further underscore the 
possible IDR-like characteristics of the NTD of 
HSPB7 being crucial for its anti-amyloidogenic 
activity. Yet, these features alone do not suffice to 
confer such activity as fusion of the NTD of HSPB7 to 
polyQ proteins directly did not reduce but rather 
enhanced polyQ aggregation (Figure 2, A-D).  
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Our combined data suggest that the NTD of 
HSPB7 drives a de-oligomerization of HSPB proteins 
that causes exposure of its IDR-like features that next 
drives binding of the HSPB to early intermediate 
aggregates of polyQ proteins, by interacting with 
regions flanking the amyloidogenic polyQ core. 
Through such interactions further oligomerization into 
amyloid like fibers is delayed (41). Alternatively early 
formed protofibrils are stabilized by HSPB7 to inhibit 
the rate of the aggregation process (41,42). 
Irrespective of either one of these mechnisms, 
aggregate growth is delayed which may facilitate their 





Cell culture and transient transfection 
HEK293 cells were grown in DMEM (GBICO) 
containing 10% FCS (Greiner Bio-one), 100 Units/ml 
Penicillin/streptomycin (Invitrogen). For transient 
transfection, 3.5×105 cells were seeded on poly-lysine 
(Sigma) pre-coated 6-well plates or cover slips. Cells 
were cultured until about 70% confluency and were 
transfected with polyethylenimine (PEI) (Invitrogen) 
following the manufacturer’s protocol. 
 
In vitro aggregation of mHtt 
Purified HSPB1 and HSPB7 (9) and a mHttQ48 
exon-1 fragment containing the N17 domain, 48 
glutamines and the PPR protein (43) were used for in 
vitro aggregate formation (9). In short, 20 µM 
mHttQ48 was incubated with 20 µM sHSPB at 37 ℃ 
for 0, 1, 2, 3, 4 and 5 hours in PBS (pH=7.4) containing 
1 mM DTT. After incubation, 8 µl of each sample was 
mixed with the same amount of denaturing buffer (180 
mM Tris-HCl, pH 6.8, 30% glycerol, 15% beta-
mercaptoethanol, 6% SDS) (43) and then immediately 
be boiled in 95 ℃ for 5 min. Samples were stored at   
-140℃ until use. Samples were boiled before loading 
onto a 12% SDS-PAGE gel. After electrophoresis, the 
gel was stained by SYPRO Orange (Sigma). Images 
were analysed using a ChemiDoc Touch Imaging 
system (Bio-Rad). Hereafter, the gel was washed in 
washing buffer (25 mM Tris base, 190 mM glycine and 
0.1% SDS, pH=8.3) for three times, followed by 
transfer onto a nitrocellular membrane for regular 
western blot analyses.  
 
Gene cloning and generation of mutants 
Construction of v5-HSPB7WT, v5-HSPB7△s17-29, 
NTDHSPB7-mRFP and mHttQ74-GFP plasmid has been 
described before (8). v5-HSPB7△16, v5-HSPB7△31, v5-
HSPB7△73, N10-Q74-PRR, N17-Q74-P10 and N10-
Q74-P10 were generated using QuickChang XL Site-
Directed Mutagenesis Kit (Agilent Technologies) with 
v5-HSPB7WT or N17-Q74-PRR (mHttQ74 full exon1) 
as templates, all steps followed the instructions of 
manufacturer. To generate v5-NTDHSPB7Q43-eGFP, 
v5-NTDHSPB7Q74-eGFP, and v5-HSPB7WT-Q74-
eGFP, v5-NTDHSPB7 (the N-terminus of HSPB7 with a 
v5 tag) or v5-HSPB7WT was cloned from v5-HSPB7WT 
by PCR, adding unique BamHI and NheI sites to the 5’ 
and 3’ terminus respectively. GFP tagged polyQ 
fragments were obtained by cuting mHttQ43-GFP and 
mHttQ74-GFP plasmids using NheI and NotI. The 
inserts were ligated into the  BamHI and NotI 
digested pcDNA3.1 vector. A similar strategy was 
used to generate v5-NTDHSPB7HSPB1 but based on v5-
HSPB7WT, empty pcDNA3.1 vector and v5-HSPB1WT 
plasimds (8). The HSPB1DDD and HSPB1AAA mutants 
have been reported before (34). 
 
Primers. 
Primer used for cloning the NTD of HSPB7: 
F: 5’-GCTACCGGATCCAGCCACAGAACCTCTTCCACCTTCCGAG-3’; 
R: 5’-CGTACGGCTAGCGCCTGCCCCACCGGGGCGGGCTGGGAA-3’.




Sucrose gradient centrifugation 
Sucrose gradient analysis was done as reported 
before (8). Briefly, transfected HEK293 cells were 
washed with PBS and lysed in 200µl NP40 lysis buffer 
(50mM HEPES, 60mM KCl, 2mM MgCl2, 10% 
glycerol, 0.4% NP40). Cell lysates were cleared 
through a 26 gauge syringe for 10 times, followed by 
centrifugation at 100000g for 16 hours using 20%-
60% sucrose gradient colum in a ultraspeed centrifuge 
using a SW41 rotor. 700µl fractions were precipitated 
by adding equal amount of 25% trichloroacatic acid. 
The pellets were washed twice using 80% acetone (-
20℃) and allowed to dry. The pellet was dissolved in 
20µl 0.1M NaOH containing 1% SDS. Equal amount 
of 2× Laemmli buffer was added and samples were 
boiled for 5 minutes before western blot analysis. 
 
Immunoblotting 
For western Blot, cells were lysed in FTA sample 
buffer (10mM Tris-HCl, 150mMNaCl, 2% SDS, 
pH=8.0) and were boiled with equal amount of 2× 
Laemmli buffer. Samples were then loaded and run on 
a 12% SDS page gel and transfered (Bio-Rad). After 
transfer, membranes were blocked and incubated with 
primary and secondary antibodies followed by 
detection using the ChemiDoc Touch Imaging system 
(Bio-Rad) 
Filter trap assays (FTA) were perfomed as 
reported before (33). In short, 3.5×105 HEK293 cells 
were seeded on 6 well plates. Cells in each well were 
lysed in 200 µl FTA sample buffer (10 mM Tris-Cl, pH 
8.0, 150 mM NaCl, 2% SDS). 100 µg, 20 µg and 4 µg 
samples were diluted in FTA sample buffer supplied 
with 50 mM dithiothreitol (DTT). Boiled samples 
were then applied onto a pre-washed (by FTA wash 
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buffer, 10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.1% 
SDS) 0.2 µM cellulose acetate filter (GE Water and 
Process Technologies, Trevose, PA, USA) with 2 
Whattman papers (Bio-Rad, Hercules, CA, USA) in a 
Bio-Dot microfiltration apparatus (Bio-Rad). Gentle 
suction was applied to filtrate the samples followed by 
three times washing using FTA wash buffer. After 
blocking the membrane for 1 h in 5% milk, incubated 
with primary (overnight) and secondary antibodies (1 
h), membrane was exposed using ChemiDoc Touch 
Imaging system (Bio-Rad). 
Primary and secondary antibodies used: mouse 
anti-v5 primary antibody (invitrogen) at a 1:10000 
dilution, anti-GAPDH primary antibody (Fitzgerald) 
at 1:10000 dilution, anti-GFP primary antibody 
(invitrogen) at1:5000 dilution, anti-HSPB1 primary 
antibody (StressMarq) at 1:2000 dilution, anti-
polyglutamine primary antibody (MAB1574, Sigma) 
at 1:1000 and sheep anti-mounse secondary anitbody 
(GE Healthcare life science) at 1:5000 dilution.  
  
Immunofluorescence 
48 hours after transfection, cells on coverslips 
were fixed in 2% formaldehyde for 15 min., washed 2 
times with PBS (pH=7.5) and permeabilized with 
PBS-TritonX100 (0.1%). Then cells were washed with 
PBS and with PBS plus (PBS with 0.5% BSA, 0.15% 
glycine), followed by primary antibody incubation 
overnight at 4 ℃. Then cells on coverslips were 
washed with PBS plus for 4 times and were incubated 
with secondary antibody. After washing with PBS plus 
and PBS DNA was stained with DAPI (Thermo Fisher 
Scientific) for 5 minutes followed by washing with 
PBS. Cover slips were mounted in vectashield (Agar 
Scientific). Mouse anti-v5 primary antibody 
(invitrogen) at a 1:10000 dilution, Alexa 594 anti-
mouse (Invitrogen) secondary antibody was diluted as 
1:1500. Images were taken by a Leica sp8 confocal 
microscope and edited by Fiji. 
 
Statistical analysis 
The software Curve Expert 1.3 was used to make 
a standard curve for measuring protein concentration. 
Differences among the experimental groups were 
analyzed by one-way analysis of variance (ANOVA) 
(P < 0.05 and P < 0.01). Values were considered to 
differ signiﬁcantly when P < 0.05. All data are 
expressed as the mean ± one standard deviation (SD).  
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Figure 1. Direct interaction with and prevention of polyQ protein aggregation by HSPB7 is dependent on its full NTD. 
A-B, HSPB7 prevents mHttQ48 aggregation in vitro. A purified exon-1 fragment of Huntingtin (mHttQ48) was incubated 
without chaperones or with either HSPB7 or HSPB1 for 0-5 hours at 37 ℃ and processed on SDS-PAA gels. A, Soluble 
mHttQ48 was detected by western blot using anti-polyQ antibody (upper row). Soluble and insoluble mHttQ48 as well as 
HSPBs levels were also detected by SYPRO orange staining of the SDS-PAA gels (lower row). “C” means control in which 
HSPB1 or HSPB7 were incubated at 37 ℃ for 5 h without mHttQ48. B, Quantification of the ratio of soluble to insoluble 
mHttQ48. C, Schematic representation of HSPB7 NTD truncated mutants. D, Filter trap assay (FTA) of the effects of HSPB7WT 
or NTD truncated mutants on polyQ (mtHttQ74) aggregation in HEK293 cells (left). Control samples were transfected with 
mRFP. Quantifications are shown on the right, normalized to control (= 1.0). E, Quantification of cells displaying mHttQ74-
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GFP aggregates when expressed together with mRFP (control =1.0), HSPB7WT or its mutants. F, Representative 
immunofluorescence pictures of HEK293 cells expressing mHttQ74-GFP with control plasmid (mRFP) or together with 
HSPB7WT or its mutants (bar=100 µm, zoom in upper right, dotted lines indicate the cell outlines). G, Immunofluorescence 
staining of HEK293 cells co-expressing mHttQ74-GFP (green) with v5-HSPB7WT (upper row in red) or v5-HSPB7Δ73 (lower 
row in red). Bar = 10 µm. H, Co-immunoprecipitation of HSPB7WT but not HSPB7Δ73 with mHttQ74-GFP. Western blot with 
the indicated antibodies is shown. All experiments were repeated at least three times. Data are presented as mean ± SD. “ * ” 





























Figure 2. The NTD of HSPB7 alone is not sufficient to prevent polyQ aggregation. 
A-D, Fusing the NTD of HSPB7 to mHttQ74-GFP does not prevent polyQ aggregation. A, Schematic representation of the 
different chimeric proteins. B, Filter trap assay (FTA) of v5-NTDHSPB7Q43-eGFP and v5-NTDHSPB7Q74-eGFP expressing 
HEK293 cells (left). Quantification of polyQ aggregation measured by FTA normalized to the control (Q43-eGFP or Q74-
eGFP respectively = 1.0) (right) . C-D, PolyQ inclusions in cells expressing v5-NTDHSPB7Q43-eGFP and v5-NTDHSPB7Q74-
eGFP. C, Quantification of cells with aggregates, corrected for the total number of cells and normalized to control (Q43-eGFP 
or Q74-eGFP respectively = 1.0). D, Representative immunofluorescence pictures of HEK293 cells expressing different 
chimeric proteins (bar = 100 µm, zoom in upper right, dotted lines indicate cell outlines). E-F, Fusing full length HSPB7 to 
mHttQ74-GFP prevents polyQ aggregation. E, Schematic representation of the chimeric proteins. F, FTA of v5-HSPB7WT-
Q74-eGFP expressing HEK293 cells. (left) and quantification of polyQ aggregation measured by FTA normalized to the 
control (Q74-eGFP alone)(right). All experiments were repeated at least three times. Data are presented as mean ± SD. “ * ” = 
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Figure 3. NTD swapping between HSPB1 and HSPB7 reveals a key role of the NTD of HSPB7 in the prevention of  
polyQ aggregation. 
A, Schematic representation of the different chimeric proteins. B, Filter trap assay (FTA) of the effect of the indicated HSPB 
variants on mHttQ74-GFP aggregation in HEK293 cells (left). As a control cells were transfected with mRFP. Quantification 
of mHttQ74-GFP aggregation is normalized to control (= 1.0) (right). C-D, mHttQ74-GFP inclusions in cells which co-express 
the indicated HSPB variants. C, Quantification of cells with aggregates per total number of cells, normalized to control (=1.0). 
D, Representative immunofluorescence pictures of HEK293 cells expressing the indicated HSPB variants (bar = 100 µm, zoom 
in upper right, cell outlines indicated by dotted lines). E, Immunofluorescence staining of HEK293 cells co-expressing 
mHttQ74-GFP (green) and v5-NTDHSPB7-HSPB1 mutant (red) or v5-HSPB1WT (red). Bar = 10 µm. F, Schematic 
representation of the different chimeric proteins. G, Filter trap assay (FTA) of the effect of the indicated HSPB variants on 
mHttQ74-GFP aggregation in HEK293 cells (left). As a control cells were transfected with mRFP. Quantification of mHttQ74-
GFP aggregation is normalized by control (-1.0) (right). H, Immunofluorescence staining of HEK293 cells showing no 
colocalization of mHttQ74-GFP (green) with v5-NTDHSPB1-HSPB7 mutant (red). Bar = 10 µm. I, Co-immunoprecipitation of 
v5-NTDHSPB7-HSPB1 but not HSPB1WT with mHttQ74-GFP but HSPB1WT. Western blot using the indicated antibidies are 
shown. All experiments were repeated for at least three times. All experiments were repeated at least three times. Data are 





























Figure 4. The relation between the oligomeric status of HSPB variants and their abilities to prevent polyQ aggregation. 
A, Sucrose gradient centrifugation analysis of HSPB variants expressed in HEK293 cell in a linear 20 – 60% sucrose density 
gradient. Representative immunoblots are presented on the left, quantitative analysis are shown on the right. B, Native gel 
electropheresis of HEK293 cells expressing HSPB1WT (WT), HSPB1DDD (DDD), or HSPB1AAA (AAA). Arrows show 
oligomeric size as large (L), medium (M) and small (S) size. GAPDH was detected by denaturing PAGE as reference. C, Filter 
trap assay (FTA) of HSPB1DDD and HSPB1AAA mutants on mHttQ74-GFP aggregation in HEK293 cells (left). Quantification 
of polyQ aggregation are normalized by control (=1.) and are shown on the right. All experiments were repeated at least three 










Figure 5. HSPB7 prevents mHtt aggregation via interactions with the polyQ flanking regions. 
A-D. Schematic representation of the constructs of different mHtt mutants are presented on the top (N17 = intact NTD; N10 
= disturbed NTD; PRR = intact proline rich region; P10 is disturbed proline rich region. Representative immunoblots of FTA 
(left panels) and quantifications (middle panels) and expression levels of different mHtt and v5-HSPB7 constructs as detected 
by western blot (right panel) are presented. All quantifications are normalized to cells transfected with mHttQ74-GFP mutants 
and mRFP (=1.0). All experiments were repeated at least three times. Data are presented as mean ± SD. “ * ” stands for P<0.05. 
 
 
